Testosterone therapy in diabetes and pre‐diabetes
Andrology · 2023-02 · 11 (2) · 204-214
DOI: 10.1111/andr.13367 ↗At a glance
Systematische Übersicht in Andrology, published online on 2022-12-29. Written by Giovanni Corona and 5 co-authors. Institution: Medical Department, Endocrinology Unit, Azienda Usl, Maggiore-Bellaria Hospital, Bologna, Italy. Major MEDLINE topics: Diabetes Mellitus, Type 2, Prediabetic State, Hypogonadism. Cited 54 times so far (Crossref); 59 references.
Topics: Diabetes mellitus
Abstract (original language)
Background
Type 2 diabetes mellitus and pre‐diabetes are associated with reduced circulating testosterone levels. However, the role of testosterone replacement therapy in these patients is still conflicting.
Objectives
To summarize and critically analyze available data on the possible effect of testosterone administration in men with glucose abnormalities. Materials and methods A comprehensive systematic review was performed. When available, meta‐analytic data were preferred. To better analyze the relationship between testosterone and the pre‐diabetes condition, a systematic analysis was performed and the data obtained with the latter search were used for a meta‐analytic approach. Finally, clinical data derived from a consecutive series of 4682 patients seeking medical care for sexual dysfunction at the University of Florence were also considered.
Results
Patients with impaired fasting glucose were characterized by a 3 nmol/L lower level of total testosterone when compared to controls. Similarly, impaired fasting glucose was associated with a 1.8‐fold increased risk of hypogonadism, when compared to subjects with normal glucose levels. Waist circumference and body mass index resulted as being the best predictors of reduced total testosterone levels. Secondary hypogonadism was two times higher in subjects with impaired fasting glucose when compared to rates observed in the general population. Testosterone replacement therapy was able to improve body composition, insulin resistance, and glucose profile both in impaired fasting glucose and type 2 diabetes mellitus whereas its role on body weight, lipid profile, and sexual function was less evident. Discussion and conclusion Weight loss and physical activities are able to improve both metabolic profile and testosterone levels. The combined approach of testosterone replacement therapy and lifestyle modifications could be suggested in symptomatic hypogonadal men to better motivate patients to perform physical activity which can eventually result in weight loss as well as metabolic profile and sexual function improvement. Whether or not these approaches can prevent the development of type 2 diabetes mellitus from pre‐clinical conditions requires more studies.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Medical Department, Endocrinology Unit, Azienda Usl, Maggiore-Bellaria Hospital, Bologna, Italy.
- Unit of Endocrinology, Diabetology and Medical Andrology, IRCSS, Humanitas Research Hospital, Rozzano, Italy.
- Mario Serio" Department of Experimental and Clinical Biomedical Sciences, Women's Endocrinology and Gender Incongruence Unit, University of Florence, Florence, Italy.
- Mario Serio" Department of Experimental and Clinical Biomedical Sciences, Endocrinology Unit, University of Florence, Florence, Italy.
ORCID profiles: Giovanni Corona, Alessandro Pizzocaro
Cite
APA
Corona, G., Vena, W., Pizzocaro, A., Vignozzi, L., Sforza, A., & Maggi, M. (2023). Testosterone therapy in diabetes and pre‐diabetes. Andrology, 11(2), 204-214. https://doi.org/10.1111/andr.13367
Vancouver
Corona G, Vena W, Pizzocaro A, Vignozzi L, Sforza A, Maggi M. Testosterone therapy in diabetes and pre‐diabetes. Andrology. 2023;11(2):204-214. doi:10.1111/andr.13367
BibTeX
@article{Corona2023,
author = {Corona, Giovanni and Vena, Walter and Pizzocaro, Alessandro and Vignozzi, Linda and Sforza, Alessandra and Maggi, Mario},
title = {Testosterone therapy in diabetes and pre‐diabetes},
journal = {Andrology},
year = {2023},
volume = {11},
number = {2},
pages = {204--214},
doi = {10.1111/andr.13367}
}
EUVIMED